QT Imaging has signed an exclusive distribution agreement with Al Naghi Medical (NMC) for its QTI Breast Acoustic CT [computed tomography] scanners and Cloud Platform in the United Arab Emirates (UAE).
Cleared by the US Food and Drug Administration (FDA), the QTI scanner provides a comprehensive 3D view of the breast anatomy. This technology eliminates contrast administration, compression, or ionising radiation.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Additionally, the QTI Cloud Platform is designed to advance breast health through imaging intelligence and biomarkers using a tiered software-as-a-service (SaaS) delivery model.
This platform will deliver tools such as automated findings classification and computer-aided diagnosis to all connected systems.
Under the agreement, there is a commitment to minimum order quantities, beginning with seven in the second quarter of 2026. The order volume is set to increase to 16 in 2027 and 20 in 2028. Overall, the agreement covers at least 43 scanners, with an expected revenue exceeding $24m.
Breast cancer prevalence has significantly increased in the UAE over the years.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataQT Imaging CEO Dr Raluca Dinu said: “We are excited to gain access to this significant market by partnering for the distribution of our technology with NMC, one of the leading medical device distributors in the UAE.
“By making breast imaging accurate, comfortable, and stress-free, we believe that our QTI Breast Acoustic CT scanner can help change the current breast cancer screening paradigm in the UAE, promoting earlier detection and improved prognoses.”
In April 2024, QT Imaging announced positive data that demonstrated its Breast Acoustic CT scan imaging technique could be used as a potential alternative to mammography for breast cancer screening in women with dense breasts or who were young.
